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Abstract
Malaria drug discovery is a challenging and difficult task due to the unavailability
of the vaccine and lack of newer drugs. The most potent artemisinin and its deriva‐
tives, widely used in combination therapies for curing malaria worldwide are also
now falling to resistance in some parts of the world. Thus, to combat malaria, new
drugs possessing high therapeutic value, minimal toxicity, rapid efficacy and low
cost are urgently needed. In this chapter, we will provide an integrated overview on
the challenges and opportunities in malaria drug discovery with more emphasis on
synthesis of peroxidic antimalarials.
Keywords: Natural Products, Quinine, Chloroquine, Artemisinin, Trioxane, Tet‐
raoxane, Malaria, Antimalarials
1. Introduction
1.1. History
The chronicle of malaria predating humanity is as ancient as mankind.[1] Malaria continues
to be a persistent menace wreaking havoc especially in tropical and subtropical regions despite
tremendous efforts toward its control and eradication. The unavailability of the vaccine and
the emergence of resistance in the parasite against nearly all existing antimalarial drugs have
attracted attention of researchers to modify the existing antimalarial drugs with improved
efficacy over older therapies and identify new compounds as appropriate clinical candidate.
Mortality from malaria is increasing at an alarming rate despite various renewed efforts and
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eradication campaigns[2] because the parasites (Plasmodium strains) responsible for the
majority of fatal infections have become resistant to the existing drugs. Malaria is also the cause
of poverty and a major hindrance to economic development, especially in sub-Saharan
countries.[3] Mostly, malaria is spread due to local transmission through female anopheles
mosquitoes. Occasionally, it can also be transmitted by exposure to infected blood products
(transfusion malaria) and also through congenital transmission. The major species of Plasmo‐
dium strains that infect humans are P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.
Among these, P. falciparum causes the most severe form of infection, which could be fatal.
The original picture of the parasitic existence and passage of malaria through historic times
remains blurred. It is uncertain whether the human population settlements preceded the
arrival of malaria within them.[3] The versions may vary from tentative to widely accepted or
even controversial based on the general scientific evidence. However, the effect of malaria
wreaking havoc to the human species is prominent, clear, and unmistakable. There was no
specific treatment for malaria until the 17th century.[4] The discovery of quinine from the bark
of Cinchona calisaya began effective treatment of malaria. Further, the synthesis of chloroquine
by Hans Andersag in 1934 introduced a cheap antimalarial drug and a substitute for quinine.
[5] Until the widespread resistance in 1960, quinoline-related antimalarial drugs played an
important role in the treatment of malaria. Fortunately, in 1972, the Chinese discovered
artemisinin from sweet wormwood plant Artemisia annua.[6] Artemisinin along with its
derivatives artemether, arteether (artemotil), and artesunate are the main treatment for malaria
that is resistant to conventional therapies.
Recent advances in the molecular genetics and biochemical technologies available for the
investigation of malaria parasites within the last half century have enabled us to gain a unique
perspective on the human health and health services in relation to malaria.[7]
1.2. Life cycle of malaria parasite
The life cycle of malaria parasites is very complex. It is completed inside two hosts, including
the humans (asexual) and the mosquitoes (sexual) (Figure 1).[8, 9] Malaria infection begins
when an infected female anopheles mosquito feeding on human blood bites and injects
sporozoites into the bloodstream. The parasites then quickly reach liver to form merozoites by
asexual multiplication. Subsequently, merozoites exit liver with the rupture of hepatic tissues
and enter the bloodstream where they invade and disintegrate red blood cells. Some mero‐
zoites transform into gametocytes, which are then circulated in the bloodstream. When the
second mosquito bites an infected human, it gets infected and intakes gametocytes. The sexual
transformation of gametocytes into ookinetes and ookinetes into oocyst takes place inside the
midgut of mosquito. Finally, sporozoites are developed from oocysts, which eventually burst,
releasing sporozoites into the salivary gland. Continued infection in humans and mosquitoes
alternatively propagates and spreads malaria.
A comparative study with human and rodent parasites revealed the activities of current
antimalarial drugs on the life cycle stages of plasmodium.[10] 8-Aminoquinolones are known
to be active for liver stage. The most currently available antimalarial drugs primarily target
the human blood cell stage. In addition to the asexual blood stage, some drugs (viz., pyronar‐
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idine and atovaquone) can also target both liver and sexual stage. Further, new stable synthetic
endoperoxides can inhibit gamete formation and gametocyte maturation.[10] Furthermore, it
is important to profile the currently available drugs for specific stage in parasite’s life cycle to
combat malaria by eradication and circumventing resistance.
1.3. Status quo
WHO has recommended artemisinin combination therapy (ACT) for the treatment of malaria.
[11] Since 2006, artemisinin-based combination therapies remain as the first-line treatment for
P. falciparum malaria replacing chloroquine and sulfadoxine/pyrimethamine. Combined with
other drugs, its derivatives, such as artesunate and artemether, can clear symptoms of malaria
in three days. However, a rise in demand has led to a shortage of artemisinin. Artemisinin-
based drugs are also more expensive than conventional treatments, in part because large doses
are required. Further, with recent reports on the emergence of resistance to artemisinin,[12] it
can be foreseen that in the near future, new armamentarium will be required to fight against
malaria. Thus, to overcome this problem, there is an urgent need to identify new chemotypes
or reexamining old molecules to transform them into an appropriate clinical candidate.
2. Drug resistance
The greatest challenge to malaria control and eradication is the emergence of malaria parasites
that are resistant to antimalarial drugs.[13] The reemergence of malaria from the areas where
Figure 1. Life cycle of malaria parasite.[9]
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it was eradicated and spread of malaria to new areas is a major threat. The World Health
Organization defined antimalarial drug resistance as the “ability of a parasite strain to survive
and/or multiply despite the administration and absorption of a drug given in doses equal to
or higher than those usually recommended but within tolerance of the subject.”[14] It was
modified later to specify that the drug in question must “gain access to the parasite or the
infected red blood cell for the duration of the time necessary for its normal action.”[15]
Antimalarial drug resistance occurs through spontaneous mutations that reduces the sensi‐
tivity to a given class of drug(s).[16] Only a single point mutation is sufficient to confer
resistance to some drugs, while multiple mutations appear to be required for others.
Sl. no Drug class Drug Resistance Mechanism of action
1.
4-Aminoquinoline
Chloroquine Since 1945
Inhibition of hemozoin
formation2. Amodiaquine Yes
3. Piperaquine Since 1980s
4. 8-Aminoquinoline Primaquine - Unknown
5.
Aryl-amino alcohol
Quinine Yes
Unknown6. Mefloquine Since 1985
7. Lumefantrine No
8.
Antifolates
Pyrimethamine Since 1967
Inhibition of DHFR
9. Trimethoprim Yes
10. Proguanil Since 2000
11. Sulfonamides Yes
12. Napthoquinone Atovaquone Since 2000 Inhibition cytochrome
13.
Antibiotic
Doxycycline
No Inhibition of proteinsynthesis and apicoplast14. Clindamycin
15.
Artemisinin
Artesunate Yes
Free radical mechanism
Heme alkylation16. Artemether Since 2001
17. Dihydroartemisinin
Table 1. Status of resistance in antimalarial drugs.
The malaria parasite has developed some level of resistance against nearly all previous
generation antimalarial drugs (Table 1). Recent research has confirmed evidence of artemisinin
resistance.[10] Although it is under investigation, immediate actions are needed to restrict
resistance to artemisinin from spreading to new areas. It is high time that we should fight this
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overwhelming menace with improved tools to aim at controlling the mosquito vector and
develop new armaments; otherwise, the future looks bleak and grim.
3. Mechanism of action
The mechanism of action of antimalarial drugs is based on the extensive studies of selected
drugs. Most drugs available for the treatment were discovered based on the serendipitous
identification of active compounds (natural, synthetic, and semisynthetic).[17] The progress
in the understanding of the biochemistry of malarial parasite has shed light on the mechanism
of action of new as well as older drugs.
It is believed that artemisinin and related drugs are transported to the food vacuole of the
parasite, where they generate free radicals upon interaction with Fe(II)-heme. These free
radical’s interaction with heme generates oxidative stress and kills the parasite.[18] The
mechanism of action of quinoline and related drugs is also well established.[19] It is shown
that the drugs enter the RBC and inhabit the digestive vacuole of parasite by simple diffusion.
The subsequent inhibition of hemozoin biocrystallization leads to the aggregation and
accumulation of cytotoxic heme in food vacuoles resulting in parasite’s death. The commer‐
cially available quinolone antimalarials target the gyrase and inhibit DNA replication. It results
in the delayed death of treated parasites by formation of abnormal apicoplasts.[20]
Based on the mechanism of action, different groups of antimalarials can be classified as follows:
• Artemisinin: binds heme iron and generates oxygen radicals
• Antifolate: inhibits DNA synthesis
• Atovaquone: collapses mitrochondrial membrane potential
• Quinoline: inhibits heme crystallization
• Antibacterial: ribosome and DNA gyrase inhibition
4. Toxicity of the antimalarial drugs
The most important determinant of drug use and its effectiveness is the patient compliance.
The toxicity of the drug must be balanced with the efficacy of the drug and the risk from
malaria, i.e., the drug should cause less harm than the disease itself. The doses given to the
patients should be taken into account in determining the treatment of malaria. The assessment
of the tolerability of many antimalarial drugs is ongoing, but evaluating adverse drug
reactions, events, side effects, and drug-related toxicity is difficult due to the unavailability of
good techniques to measure the side effects.[21]
The most promising naturally occurring sesquiterpene lactone drug and its derivatives
(artemether, arteether, and sodium artesunate) did not show any serious side effects. However,
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insufficient clinical trials to detect the toxicity stopped us from declaring artemisinin 100%
safe. However, they have excellent safety profile and remarkable efficacy. The current
knowledge obtained from the laboratory and clinical study is that the long-term availability
of artemisinins may cause toxicity (rarely produce neurotoxicity and allergic reactions).[22]
The short-term peak concentrations followed by rapid elimination of artemisinins after oral
intake is relatively safe compared to administration by intramuscular injection. Evidently, the
majority of animal experiments showed considerable toxicities in contrast to human studies.
Chloroquine, considered being a safe drug even at higher doses, also causes mild side effects
such as reversible effect on optical accommodation, which can potentially affect eyesight. It
also binds irreversibly to melanin. Hence, the patients with rheumatoid arthritis treated with
the long-term use of high dose chloroquine suffer from accumulation of chloroquine in retinal
melanin. Some reports also suggest that chloroquine administered to patients with light
intolerant disease can aggravate psoriasis.[22] Proguanil is also assumed to be safe at a dose
of 200 mg a day. However, for doses higher than 200 mg, there are reports of reversible alopecia
and aphthous ulceration, nausea, and gastric irritation.[23] These side effects are common with
other antimalarial agents as well. The combination of chloroquine with proguanil has good
tolerability. However, gastrointestinal upset and mouth ulcers are still observed. Sulfadoxine/
pyrimethamine is also well tolerated, but it is no longer used because it causes Stevens–Johnson
syndrome and toxic epidermal necrolysis. Mefloquine is another valuable drug for the
treatment of malaria. Despite good tolerability to most patients, dose-related serious neuro‐
psychiatric toxicity can occur. Cardiovascular or CNS toxicity is rare for quinine but hypogly‐
cemia may occur. Further, due to its potential for cardiotoxicity, halofantrine is unsuitable for
widespread use. Mepacrine, sulfonamides, dapsone, and amodiaquine are also withdrawn
from the use because of the high frequency of adverse side effects.[24]
5. Malaria vaccine
Malaria vaccine development is a challenging and difficult task because of the antigenic
complexity and the complex life cycle of malaria parasite. Research on the development of
malaria vaccine is of prime importance because such a discovery can prevent millions of deaths
worldwide. The currently available tools are insufficient for malaria eradication. Malaria
vaccine could be a transformative tool to help in reduced transmission and future eradication.
Extensive research has been carried out in the last two decades, and several vaccines have
reached clinical trials, but there is none in the clinical practice due to insufficient immunoge‐
nicity. Although parasite vaccines are in development, there is no FDA-approved vaccine for
organisms more complex than viruses and bacteria.[25]
5.1. Scientific challenges
The significant hurdle in the development of malaria vaccine is insufficient knowledge about
the malaria parasite. Understanding the structure and antigenic variation of parasite popula‐
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tion requires lengthy, tedious, and difficult lab and field studies. Antigenic variation and
parasite polymorphism also create a major scientific barrier. Unfortunately, in nature, there
are not many good examples of immunity to malaria, and many vaccine development
programs are based only on naturally acquired immunity. Since the mechanism of immune
protection is still unknown, it is difficult to comprehend why certain people are protected while
others are not. Inadequate animal models and lack of clarity in the definition of desired
outcomes create confusion in choosing the best approach to develop a malaria vaccine. Even
in particular animal model systems with defined outcomes, there is always uncertainty in
translating the success of protection in the model systems with success in humans.[26]
The malaria vaccine development includes recombinant proteins, gene-based (DNA or viral
vector) vaccines, attenuated whole organisms, peptides, and prime-boost strategy, which
involves a combination of different antigen delivery systems encoding the same epitopes or
antigen using various adjuvants. Reports dating back to 1960s[26] demonstrated species-
specific and strain cross-reactive protection on immunization with radiation-attenuated
sporozoites in primate and experimental rodent models. Studies showed optimistic levels of
protective immunity. However, the volunteers immunized against multiple strains of P.
falciparum malaria were not protected against P. vivax. The target antigens were identified from
the sera cells of experimental hosts immunized with attenuated sporozoite vaccine and
protected volunteers. Circumsporozoite protein, the first cloned and sequenced malaria
parasite in P. knowlesi and P. falciparum, is also the first antigen identified by serological
screening. It plays an important role in protection. When the sporozoite was irradiated in the
rodent models, antibody and cells showed different roles in malaria species and different
strains. Although multifaceted cellular responses are observed, the basic mechanism of
immunity is believed to target the intracellular hepatic exoerythrocytic forms by the produc‐
tion of interferon. The antibody eliminates most of the infectious sporozoite inoculum, when
the vaccines prove a multipronged approach. The cellular responses target the rest of the
intracellular exoerythrocytic forms by direct cytotoxicity or inhibitory cytokines.
The understanding of the research related to vaccine development is greatly benefitted by the
lessons learned from discontinued and inactive projects. Recent findings allow us to be
optimistic about the possibility of an effective malaria vaccine. Several malaria vaccine
candidates have entered field trials. It is now possible to impact the host–parasite relationship
using different platforms through vaccine-induced immune responses to multiple antigenic
targets. The field has grown rapidly over the last two decades from the first clinical trials to
the successful conduct of large-scale field studies, and substantial progress has been made in
evaluating many antigens. Despite the daunting task, researchers have produced surprising
progress in several areas. The malaria vaccination program has progressed to an assessment
and clinical evaluation of RTS,S/AS01E in phase 3 trial.[27] The first malaria vaccine may be
considered for licensure in the coming years. Further, there is a possibility of developing more
efficacious second-generation vaccines. Researchers are now better equipped to establish clear
product profiles. The lessons learned in terms of safety, immunogenicity, efficacy, and trial
methodology from malaria vaccine research is summarized in Table 2.
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Parameters Remarks
Safety
⋅ It is often lower in semi-immune populations living in endemic areas than in naïve
populations
⋅ Reactogenicity in young children has not been worse than in adult populations
Immunogenicity ⋅ DNA alone is poorly immunogenic
⋅ Little clinically significant interference is observed between vaccine antigens and the
malarial antigen
Efficacy ⋅ Only RTS,S-based vaccines proved to be effective to reduce morbidity in endemic areas
⋅ Highly polymorphic blood-stage antigens have tended to lead to allele-specific efficacy, but
poor efficacy against the population of circulating strains
Methodology ⋅ In vitro studies and animal studies does not correlate well
⋅ For testing of new malaria vaccines, ethical and methodological issues may arise
⋅ There is a need to make formal trial design for phase trials and sample size calculations.
Epidemiological studies are required to assess the effectiveness of mosquito antigen vaccines
in sexual stage
Table 2. Lessons from two decades of malaria vaccine development research.
6. Antimalarial drugs
Malaria, existing in over 100 countries, is one of the deadliest infectious diseases and major
health problem worldwide. Antimalarial drugs are designed to cure malaria, many of which
are in market.[28] From the 17th century onward quinine had been the drug of choice for the
treatment of malaria. Later on, medication therapies heavily relied on chloroquine, prima‐
quine, mefloquine, etc.4 These drugs especially chloroquine have saved more lives than any
other drugs in history. Recently, artemisinin and its derivatives have emerged as a new
generation of antimalarials (Figure 2).
There is a critical need to develop newer synthetic and more effective drugs that could address
the issues associated with the existing and traditional drug therapies. The availability of
artemisinin also causes supply constraints because artemisinin and its derivatives constitute
an active ingredient of many combination therapy dugs. For example, Coartem contains a fixed
combination of artemether and lumefantrine. In 2012, Ranbaxy also launched a new synthetic
peroxide antimalarial drug SynriamTM in the market in line with the recommendations of the
WHO. It is a fixed dose combination of arterolane maleate and piperaquine phosphate. The
chemical structures are shown below.
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Figure 2. Antimalarial drugs.
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Research groups across the world are united in the efforts to discover new chemicals for the
treatment of malaria. Attempts to modify the established drugs are also ongoing. Long-term
hopes are resting on the modification of the synthetic artemisinin-based drugs containing
endoperoxide rings. The following sections will mainly focus on the development of peroxidic
antimalarial agents.
6.1. Natural products
Natural products continue to make an immense contribution to malaria chemotherapy. The
discovery of quinine and artemisinin proves that nature is a rich source of lead compounds
that can provide cure and medicine for malaria. Nature has been extremely generous when it
comes to search of new molecular scaffolds for good malarial activity. These scaffolds later
serve as template for the development of structurally diverse analogues with more potent
activity.[29] For example, quinine a bitter-tasting alkaloid, is one of the earliest natural
compounds that helped man in the fight against malaria. It was isolated from the Cinchona
bark. Later, it also served as a template for the synthesis of more potent and structurally simpler
analogues such as chloroquine, primaquine, mepacrine, and mefloquine (Figure 2). Artemisi‐
nin extracted from Artemesia annua is another example whose diverse pharmacological
potential has attracted the researchers worldwide. Artemisinin also gave rise to the develop‐
ment of dihydroxyartemisinin, artemether, arteether and artesunate. Thus, natural products
such as quinine and artemisinin have demonstrated the enormous potential of nature in
providing lead compounds, which can be further manipulated structurally for the develop‐
ment of more effective antimalarial agents. Many more natural products possessing various
chemical structures, such as alkaloids, steroids, chalcones, terpenes, flavonoids, peptides,
quinones, xanthones, coumarines, naphthopyrones, polyketides, phenols, lignans, chromenes,
etc., have been tested as antimalarial drugs.[30, 33]
6.2. Semisynthetic drugs
The success of the most potent antimalarial drugs, quinine and artemisinin, has brought some
optimism. Due to the widespread emergence of drug-resistant chloroquine, primaquine,
mepacrine, and mefloquine (Figure 2) were developed. Despite the remarkable antimalarial
activity, artemisinin suffers from limited availability, low solubility, high cost, metabolic
stability, short half-life, poor bioavailability, and chemical stability. Thus, there is a need for
new compounds more active than the parent artemisinin. To circumvent some of these
problems, semisynthetic analogs were prepared. The reduction of artemisinin yields dihy‐
droartemisinin, and the lactol group can be further converted to its ether (artemether, arteether,
and artelinic acid) and ester (sodium artesunate) derivatives.[34]
6.3. Synthetic drugs
Artemisinin, a sesquiterpene endoperoxide, has established the role of peroxide ring for
potential antimalarial activity. However, the naturally isolated artemisinin is available in short
supply and expensive to synthesize. As a consequence, extensive research directed towards
the discovery of peroxidic antimalarials inspired researchers to explore structurally simple
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peroxides. Trioxanes, tetraoxanes, and their hybrids were consequently identified as promis‐
ing candidates for the development of next generation antimalarial drugs.
6.3.1. Various synthetic procedures for the synthesis of trioxanes
Trioxanes can be synthesized from inexpensive starting materials, and their scale-up prepa‐
rations are feasible. Most methods reported for the synthesis of trioxanes starts with the
reaction of singlet oxygen with carbonyls in the presence of Lewis acids. Then acid-catalyzed
cyclization of hydroxyperoxides with olefins and reaction of α-peroxy aldehydes with
carbonyl compound yields trioxanes in good yields. Many synthetic strategies were developed
for the synthesis 1,2,4-trioxanes, which are described below.
6.3.1.1. Photooxygenation method
Starting from commercially available cyclohexanediones, tricyclic 1,2,4-trioxanes can be
synthesized by following simple method. Briefly, photooxygenation of the electron-rich allylic
alcohols 1 using singlet oxygen gives β-hydroxyperoxide 2. Further, β-hydroxyperoxide 2 was
condensed with 1,4-cyclohexadiene followed by Lewis acid-mediated cyclization to give keto-
trioxane 3. Amino functionalized trioxanes 4 were also synthesized on reductive amination
with various amines in the presence of sodium triacetoxy borohydride (Scheme 1).[35]
Sheme 1. Photooxygenation method for trioxane synthesis.
In another synthetic procedure, the geranyl acetate was transformed into aldehyde acetate 5,
which is converted into allylic alcohol 6. Photooxygenation of 6 followed by subsequent acid
catalyzed condensation of β-hydroxyhydroperoxides 7 with various ketones resulted in the
formation of new 1,2,4-trioxanes 8 (Scheme 2).[36] The hydroxyl functionalized side chains can
be further manipulated for the synthesize of a diverse library of compounds.
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Sheme 2. Synthesis of Geraniol derived 1,2,4-trioxanes.
6.3.1.2. Epoxidation method
The epoxidation of N-Boc piperidone 9 gives N-Boc spirooxirane 10. Dispiro N-Boc-protected
1,2,4-trioxane can then be synthesized by MoO2(acac)2 catalyzed perhydrolysis of N-Boc
spirooxirane 10, as shown in Scheme 3.[37] Subsequent condensation of the resulting β-
hydroperoxy alcohol 11 with 2-adamantanone gives N-Boc 1,2,4-trioxane 12, which can be
converted into the amine 1,2,4-trioxane hydrochloride salt 13. Further, alkylation may result
in a diversified sulfonamide trioxane derivatives 14.
Sheme 3. Trioxane synthesis using epoxidation method.
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6.3.1.3. Catalytic enantioselective synthesis
Trioxanes can also be synthesized by catalytic enantioselective synthesis. Para-cresol 15 is
converted into p-peroxyquinols 16. The desymmetrization of p-peroxyquinols 16 occurs via an
acetalization/oxa-Michael cascade reaction (Scheme 4).[38] The reaction proceeds via a
dynamic kinetic resolution of a peroxyhemiacetal intermediate. Various derivatized trioxanes
17 can be easily obtained by this method. The use of chiral Brønsted acid catalyst TRIP 18 gave
a single diastereomer trioxane 17 in 86% ee, while using bis-(2,4,6-triisopropylphenyl)spiro‐
biindane phosphoric acid 19 gave 96% ee. The use of thiourea 20 as cocatalyst helped to restore
the reactivity even at lower catalyst loading.
Sheme 4. Enantioselective synthesis of trioxanes.
6.3.1.4. Solid phase synthesis
The solid support synthesis of 1,2,4-trioxanes also needs light mediated oxygenation on
polystyrene polymer support. Wang and Rink amide resins can be used as linkers. The reaction
of resin-bound p-carboxybenzaldehydes 21 with excess of ionone derivatives 22 gave immo‐
bilized dienones 23 in the presence of LiOH in DME (Scheme 5).[39] Resin-bound trioxane 24
was obtained upon irradiation of compound 23 with UV light (354 nm) in toluene yielded.
After cleavage from the solid support, the formation of 25 was confirmed by 13C NMR. Peaks
at 82.4 and 94.4 ppm corresponded to the peroxy-bearing carbon and peroxyketal carbon of
the trioxane ring system.
6.3.2. Various synthetic procedures for the synthesis of tetraoxanes
The chemical modification of artemisinin retaining the crucial endoperoxide ring has resulted
in yet another simplified structure known as 1,2,4,5-tetraoxane. Tetraoxanes show significantly
higher stability and exhibit even higher activity than natural peroxidic drugs for curing malaria
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infections. In 1899, Baeyer and Villiger reported the synthesis of the first dimeric acetone
peroxide upon treatment of acetone and Caro’s acid in ether. Since then, the field has moved
ahead significantly and newer synthetic routes and efficient methodologies were developed.
The synthesis can be carried out by several methods as described below.
6.3.2.1. Peroxidation method
The most commonly and widely used method for tetraoxane synthesis is known as peroxida‐
tion method. In this method, acid-catalyzed cyclocondensation of ketones or aldehydes gives
the gem-dihydroperoxide as an important active intermediate. Generally, the acid-catalyzed
addition of hydrogen peroxide to carbonyl compound 26 produce gem-dihydroperoxide 27,
which on subsequent cyclocondensation in the presence of strong acid such as sulfuric acid,
perchloric acid, or methanesulfuric acid yield more stable symmetrical tetraoxane 28 along
with side product hexaoxane 29, as shown in Scheme 6. It is also known that the trimeric cyclic
peroxide by-product hexaoxonane is formed in the presence of excess hydrogen peroxide.
Dimethyl sulfide and potassium iodide can be used for the removal of hydroperoxide-related
impurities. Hexaoxonanes could be removed by washing the reaction mixture with cold
methanol. [40]
In our lab, we also attempted the synthesis of a new series of tetraoxane by incorporating
nitrogen within the cyclohexyl ring. [41] Methyl 2-(4-oxopiperidin-1-yl)acetate 30 on reaction
with gem-dihydroperoxide 27 may give very small amount of tetraoxane 31 and trimer 29, as
shown in Scheme 7. We characterized hexaoxonane 29 as a main side product by spectroscopy
and x-ray crystallography.
Sheme 5. Solid phase trioxane synthesis.
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Sheme 7. Synthesis of piperidinetetraoxane
6.3.2.2. One pot synthesis
Iskara et al.[42] developed the first one-pot synthesis of tetraoxane. Simple carbonyl com‐
pounds 32 in the presence of 30% H2O2, 0.1% MTO, and fluorous alcohols (TFE and HFIP)
selectively gives tetraoxanes 33 (Scheme 8). Fluorous solvents TFE and HFIP activate both
H2O2 and MTO for oxidation reactions. The one-pot synthesis of mixed tetraoxanes begins with
the oxidation of the most reactive carbonyl compound, and then less oxidizable carbonyl
compound is added in the presence of acid. In this reaction, no trimeric product is formed.
Sheme 8. One pot tetraoxane synthesis.
Sheme 6. Acid catalyzed synthesis of tetraoxanes and hexaoxonanes.
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6.3.2.3. Ozonolysis method
The most prolific strategy for the synthesis of tetraoxanes is the ozonolysis of suitable olefins
and oximes. This method has dual advantage over others: (1) the absence of hexaoxonane (a
usual by-product), which is very common in acid catalyzed reactions, and (2) it is useful for
the synthesis of aromatic tetraoxanes, which could not be obtained by other methods. In the
1970s, Keul et al. reported the synthesis of dimeric adamantine peroxide 35 by ozonization of
methyleneadamantane 34 in pentane at –78°C. The ozonolysis of valerophenone oxime o-
methyl ether 36 produces carbonyl oxide 38 via an intermediate ozonoid 37 to give the
crystalline dimeric valerophenone peroxides 39 in the absence of carbonyl compounds or
protic solvents.[43]
Sheme 9. Tetraoxane synthesis by ozonolysis method.
7. Prodrug and combination therapies
The search of newer drugs and the enhancement of antimalarial activity of the existing ones
have led to the development of prodrug and combination therapy approaches. It presents a
good platform for the usage of readily available drugs in combination with other effective
drugs. The potential of drug hybrids, prodrugs, and combination therapy as new approaches
are immense.[44]
Tetraoxaquine 40 contain two covalently linked pharmacophores, i.e., a tetraoxane (a radical
donor) and an aminoquinoline (interferes with hematin polymerization).[45] Moreover,
trioxaquine 41 contains covalently attached trioxane to a 4-aminoquinoline moiety.[46] The
chimeric drug penetrates (enabled by aminoquinoline) into infected erythrocyte and targets
the free heme. The hemoglobin digestion of the schizonts within infected red blood cells
liberates free heme, which is alkylated by the peroxidic part. Trioxaferroquine 42 consists of a
trioxane, a substituted quinoline, and an iron (II) species within a single structure.[47]
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These new chimeric molecules containing two covalently attached moieties can be expected
to possess synergistic therapeutic value, reduce resistance, and toxicity. These strategies offer
a rational drug design approach for the development of next generation drug candidates.
Notwithstanding few selected examples, which are discussed in this section, it explains the
concept and potential applications.
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8. Conclusion and future prospect
The development of new drugs for malaria presents a challenging situation. Lack of alterna‐
tives and increasing ineffectiveness of the existing drugs are the main reasons for increased
mortality. Traditional medicines have provided few drugs, but to combat malaria, new drugs
are urgently needed. These new drugs must ideally possess minimal toxicity, rapid efficacy,
and low cost. However, there is consensus among scientific community that drug combina‐
tions may create optimal control of malaria because the combination therapies are believed to
be additive in potency, provide synergistic activity, and is more advantageous than mono‐
therapies. Unfortunately, these requirements are not met by any combination at the current
window of time. Besides all the challenges, failures, and setbacks, the global importance of
fighting malaria is recognized. Dedicated efforts and academic engagement to discover,
develop, and deliver new, effective, and affordable antimalarials have thus increased dramat‐
ically. Natural products, semisynthetic drugs, and synthetic compounds offer vast opportunity
for the drug development process. Further, assessment and clinical evaluation of RTS,S/AS01E
for malaria vaccination offers hope that we may soon expect some good news. Malaria drug
discovery is undoubtedly challenging, but scientists are optimistic as they also have got various
opportunities too. The status quo seems balanced. However, we believe that we have to provoke
the status quo to gain the upper hand in the battle against this tropical scourge.
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